TSE:RKV Stock Latest News
Company AnnouncementsRakovina and Celvion Use AI to Prioritize Brain-Penetrant ATR Cancer Program5d ago
Company AnnouncementsRakovina and Variational AI Push Brain-Penetrant ATR Program Toward Candidate Selection1w ago- Company AnnouncementsRakovina Wins Exclusive Rights to AI-Optimized kt-5000 Cancer Drug Profile2w ago
Company AnnouncementsRakovina taps Celvion’s AI platform to sharpen precision oncology strategy1M ago
Company AnnouncementsRakovina Therapeutics Adds Yale DNA Repair Expert to Scientific Advisory Board1M ago
Company AnnouncementsRakovina Therapeutics Narrows Q2 Loss as AI-Focused Cancer Pipeline Advances2M agoCompany AnnouncementsRakovina Therapeutics Closes Upsized $1.99 Million Private Placement to Advance AI-Driven Cancer Pipeline2M ago
Company AnnouncementsRakovina Therapeutics Tightens Board, Keeps Incentive Plan as It Advances AI-Driven Cancer Pipeline2M ago
Company AnnouncementsMethanex Declares Quarterly Dividend, Reinforcing Shareholder Payout Strategy3M ago
Company AnnouncementsRakovina leverages AI to advance next‑generation cancer drug candidates7M ago- Company AnnouncementsRakovina Therapeutics Extends Private Placement to Bolster Working Capital7M ago
Company AnnouncementsRakovina Raises $1 Million and Restructures Debt to Bolster Cancer Drug Development8M ago
Company AnnouncementsRakovina Therapeutics Upsizes Financing to $2 Million for Near-Term Operations8M agoCompany AnnouncementsRakovina Gains DDR Momentum with Brain-Penetrant ATR Strategy and ADC Interest9M ago
Company AnnouncementsRakovina Therapeutics Moves to Bolster Finances With Debenture Deal, Equity Raise and Debt Overhaul9M ago
Company AnnouncementsRakovina and Variational AI Deepen Partnership to Fast-Track Next-Gen ATR Cancer Drugs9M ago- Company AnnouncementsRakovina Therapeutics to Seek Strategic Partnerships During JPM Week10M ago
Company AnnouncementsRakovina Therapeutics to Host Webinar on AI-Driven Cancer Therapies10M ago
Company AnnouncementsRakovina Therapeutics Reports Q3 2025 Financial Results and Highlights Strategic Advances11M ago
Company AnnouncementsRakovina Therapeutics Secures Debenture Extension Amid Expired Warrant Program11M agoCompany AnnouncementsRakovina Therapeutics Advances AI-Derived PARP-1 Inhibitor Program at SNO 202511M ago
